OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
Jeffrey Fudin,1,2 Mena Raouf,3 Erica L Wegrzyn4
1REMITIGATE, LLC, 2Stratton Veteran Affairs Medical Center, Albany, NY, 3Veteran Affairs Tennessee Valley Healthcare System, Alvin C York Campus, Murfreesboro, TN, 4Stratton Veteran Affairs Medical Center, Albany, NY, USA
Extended-release (ER) or long-acting (LA) opioids are increasingly used for management of chronic pain. Approximately 3.8 million patients receive prescriptions for ER/ LA opioids in the US.1 The number of prescriptions dispensed for ER/LA has more than doubled over the past decade, increasing from 9.3 million in 2000 to 22.9 million in 2009. Consequently, in 2012, the US Food and Drug Administration (FDA) developed a risk evaluation and mitigation strategy for ER/LA opioids.2
Jeffrey Fudin is associated with the following: Astra Zeneca (Speakers Bureau, Advisory Board), Clarity (Consultant), DepoMed (Advisory Board, Speakers Bureau), Endo (Consultant, Speakers Bureau), Kaléo (Speakers Bureau, Advisory Board), Kashiv Pharma (Advisory Board), KemPharm (Consultant), Pernix Therapeutics (Speaker), Remitigate, LLC (Owner), and Scilex Pharmaceuticals (Consultant). This article is the sole work of the authors, and stated opinions/assertions do not reflect the opinion of employers, employee affiliates, and/or pharmaceutical companies listed. It was not prepared as part of the authors duty as federal employees. The authors report no other conflicts of interest in this work.
United States Food and Drug Administration. Outpatient Prescription Opioid Utilization in the U.S., Years 2000–2009. July 22, 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf. Accessed July 5, 2016.
United States Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids. July 9, 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm. Accessed July 5, 2016.
Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257–1317.
Stamer UM, Bayerer B, Stüber F. Genetics and variability in opioid response. Eur J Pain. 2005;9(2):101–104.
Duragesic (fentanyl transdermal system) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014.
OxyContin (oxycodone HCl extended-release) package insert. Stamford, CT: Purdue Pharma L.P.; 2015.
Ryan H, Girion L, Glover S. ‘You want a description of hell?’ OxyContin’s 12-hour dosing problem. LA Times. May 5, 2016. Available from: http://www.latimes.com/projects/oxycontin-part1/. Accessed July 4, 2016.
Department of Health and Human Services [webpage on the Internet]. Available from: https://www.regulations.gov/contentStreamer?documentId=FDA-2004-P-0294-0051&attachmentNumber=1&disposition=attachment&contentType=pdf. Accessed July 27, 2016.
Richard Blumenthal Attorney general [webpage on the Internet]. Available from: http://www.fda.gov/ohrms/dockets/dailys/04/jan04/012804/04p-0043-cp00001-01-vol1.pdf. Accessed July 27, 2016.
FDANEWS [webpage on the Internet]. Available from: http://www.fdanews.com/articles/105468-state-takes-oxycontin-label-dispute-tocourt?v=preview. Accessed July 27, 2016.
Fudin J, Atkinson TJ. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Pain Med. 2014;15(5):723–725.
Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol. 2011;67(5):493–506.
OxyContin (oxycodone controlled release) archived package insert. Stamford, CT: Purdue Pharma L.P. 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020553s059lbl.pdf
Kim DY, Song HS, Ahn JS, Ryoo BY, Shin DB, Yim CY, Kim SY. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Support Care Cancer. 2010;19(2):297–301.
Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996;18(1):95–105.
Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–758.
Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602–612.
Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3(5):377–384.
Rubinstein AL, Carpenter DM, Minkoff JR. Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. Clin J Pain. 2013;29(10):840–845.
Kaplan R, Parris WC, Citron ML, Zhukovsky D, Reder RF, Buckley BJ, Kaiko RF. Comparison of controlled-release and immediate-release oxycodone tablets AVINZA and chronic noncancer pain – 263 inpatients with cancer pain. J Clin Oncol. 1998;16(10):3230–3237.
Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, Lacouture PG. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26(4):862–869.
Klepsted P, Kaasa S, Jystad A, Hval B, Borchgrevink PC. Immediate or sustained-release morphine for dose finding during start of morphine to cancer patients: A randomized, double-blind trial. Pain. 2003;101(1–2):193–198.
McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181–186.
Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. Clin J Pain. 2004;20(5):363–366.
Weissman DE, Haddox JD. Opioid pseudoaddiction–an iatrogenic syndrome. Pain. 1989;36(3):363–366.
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Journal of Pain Research ‘Editorial’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Pain Research editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]